INGN / Inogen: Still Struggling, But Very Cheap - Upgrading To Buy

Inogen (INGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wal more_horizontal

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock. more_horizontal

Inogen's (INGN) latest acquisition is expected to expand its global Respiratory Care presence and potentially address a large growing bronchiectasis m more_horizontal

Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall second-quarter results reflect soft performances. more_horizontal

Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considerin more_horizontal

Inogen, Inc. (NASDAQ:INGN ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Agnes Lee - Senior Vice President, Investo more_horizontal

Inogen (INGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.02 more_horizontal

Inogen's (INGN) latest acquisition is expected to leverage its commercial infrastructure and capabilities as well as potentially address a large growi more_horizontal